JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pacifici, R.
Right arrow Articles by Torre, R. d. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pacifici, R.
Right arrow Articles by Torre, R. d. L.

Vol. 296, Issue 1, 207-215, January 2001

Acute Effects of 3,4-Methylenedioxymethamphetamine Alone and in Combination with Ethanol on the Immune System in Humans

Roberta Pacifici, Piergiorgio Zuccaro, Candido Hernández López, Simona Pichini, Simonetta Di Carlo, Magi Farré , Pere Nolasc Roset , Jordi Ortuño, Jordi Segura and Rafael de La Torre

Clinical Biochemistry Department, Istituto Superiore di Sanità, Roma, Italy (R.P., P.Z., S.P., S.D.C.); and Pharmacology Unit, Institut Municipal d'Investigació Mèdica (IMIM) (C.H.L., M.F., P.N.R., J.O., J.S., R.d.L.T.), Universitat Autònoma de Barcelona (M.F., P.N.R., R.d.L.T.) and Universitat Pompeu Fabra (J.S.), Barcelona, Spain

Cell-mediated immune response and release of cytokines after the administration of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") alone and in combination with ethanol were assessed in a double blind, randomized, crossover, controlled clinical trial. Six healthy male recreational users of MDMA participated in four different experimental sessions, with a washout interval between sessions of 1 week, in which single oral doses of MDMA (100 mg), ethanol (0.8 g/kg), the combination of both drugs, and placebo were tested. Acute MDMA administration produced a time-dependent immune dysfunction in association with serum concentrations of the drug as well as cortisol stimulation kinetics. Although total leukocyte count remained unchanged, there was a decrease in the CD4 T/CD8 T-cell ratio due to a decrease in both the percentage and absolute number of CD4 T-helper cells and simultaneous increase in natural killer (NK) cells. Ethanol consumption produced a decrease in T-helper cells and B lymphocytes. The combination of MDMA and ethanol caused the highest suppressive effect on CD4 T cells and increasing effect in NK cells. Drugs treatment produced a high increase of immunosuppressive cytokines (transforming growth factor-beta and interleukin-10) and a switch from Th1-type cytokines (interleukin-2 and interferon-gamma ) to Th2-type cytokines (interleukin-4 and interleukin-10). Disregulation in the production of pro- and anti-inflammatory cytokines with an unbalance toward anti-inflammatory response was also observed. The immune function shows a trend toward baseline levels at 24 h after MDMA kinetics. This transient defect in immunological homeostasis, if temporarily repeated, might alter the immune response with a risk for the general health status.


0022-3565/01/2961-0207$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
M. Mueller, F. T. Peters, H. H. Maurer, U. D. McCann, and G. A. Ricaurte
Nonlinear Pharmacokinetics of ({+/-})3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") and Its Major Metabolites in Squirrel Monkeys at Plasma Concentrations of MDMA That Develop After Typical Psychoactive Doses
J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 38 - 44.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
G. J. H. Dumont and R. J. Verkes
A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers
J Psychopharmacol, March 1, 2006; 20(2): 176 - 187.
[Abstract] [PDF]


Home page
Br. J. Ophthalmol.Home page
O M Zwick, D H Fischer, and J C Flanagan
"Ecstasy" induced immunosuppression and herpes zoster ophthalmicus
Br. J. Ophthalmol., July 1, 2005; 89(7): 923 - 924.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. J. Connor, A. Harkin, and J. P. Kelly
Methylenedioxymethamphetamine Suppresses Production of the Proinflammatory Cytokine Tumor Necrosis Factor-{alpha} Independent of a {beta}-Adrenoceptor-Mediated Increase in Interleukin-10
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 134 - 143.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. Pacifici, S. Pichini, P. Zuccaro, M. Farre, M. Segura, J. Ortuno, S. Di Carlo, A. Bacosi, P. N. Roset, J. Segura, et al.
Paroxetine Inhibits Acute Effects of 3,4-Methylenedioxymethamphetamine on the Immune System in Humans
J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 285 - 292.
[Abstract] [Full Text]


Home page
JAMAHome page
R. Pacifici, P. Zuccaro, S. Pichini, P. N. Roset, S. Poudevida, M. Farre, J. Segura, and R. de la Torre
Modulation of the Immune System in Cannabis Users
JAMA, April 16, 2003; 289(15): 1929 - 1931.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Hernandez-Lopez, M. Farre, P. N. Roset, E. Menoyo, N. Pizarro, J. Ortuno, M. Torrens, J. Cami, and R. de la Torre
3,4-Methylenedioxymethamphetamine (Ecstasy) and Alcohol Interactions in Humans: Psychomotor Performance, Subjective Effects, and Pharmacokinetics
J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 236 - 244.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.